NexP™ Fusion Technology
As various long-acting or slow-release technologies are being used and deployed globally, the NexP™ fusion technology of Alteogen is a second-generation long-acting technology, which uses DNA recombination and human A1AT (alpha-1 antitrypsin) protein, abundant in human blood, as the protein carrier in order to increase half-life of any biologics.
The safety of A1AT has been assured as the protein has been used as a pulmonary emphysema medicine for many years.
* Increased half-life
* Eliminated intrinsic activity in order to use as a safe carrier
Therapeutic proteins or peptides fused with NexP™ show excellent long-acting properties without causing any loss of activity as medicines. In pharmacokinetics and pharmacodynamics preclinical studies, the experimental drugs by NexP™ fusion technology demonstrated significantly increased in-vivo half-life and improved potency that serve the promising features of less frequent dosing, less side effects and better clinical efficacy.
NexP™ can be fused at either C- or N-terminus of proteins or peptides. This NexP™ fusion technology is a platform technology for developing next generation long-acting therapeutics.